Curium - A Multi-Center, Open-Label, Randomized Phase 1/2 Study of Copper Cu64PSMA I&T Injection in Patients with Histologically Proven Metastatic Prostate Cancer

This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.

Principal Investigator: Dr. Medhat Osman
Study Coordinator: Brittany Minor

This study is currently enrolling. To learn more about CURIUM and how you can join contact our research office at (314) 289-7690.

This study is funded by the Foundation through the sponsor CURIUM